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Abstract
Purpose: To assess efficacy of our single-centre experience with inhalative steroids (IS) in lung cancer patients with
symptomatic radiation pneumonitis (RP) grade II.
Material and methods: Between 05/09 and 07/10, 24 patients (female, n = 8; male, n = 16) with lung cancer
(non-small cell lung carcinoma [NSCLC]: n = 19; small cell lung cancer [SCLC]: n = 3; unknown histology: n = 2)
and good performance status (ECOG ≤1) received definitive radiotherapy to the primary tumour site and involved
lymph nodes with concurrent chemotherapy (n = 18), sequential chemotherapy (n = 2) or radiation only (n = 4) and
developed symptomatic RP grade II during follow-up. No patient presented with oxygen requiring RP grade III. The
mean age at diagnosis was 66 years (range: 50–82 years). Nine patients suffered from chronic obstructive pulmonary
disease (COPD) before treatment, and 18 patients had a smoking history (median pack years: 48). The mean lung dose
was 15.5 Gy (range: 3.0–23.1 Gy). All patients were treated with IS. If a patient’s clinical symptoms did not significantly
improve within two weeks of IS therapy initiation, their treatment was switched to oral prednisolone.
Results: All 24 patients were initially treated with a high dose IS (budesonide 800 μg 1-0-1) for 14 days. Of the patients,
18 showed a significant improvement of clinical symptoms and 6 patients did not show significant improvement of
clinical symptoms and were classified as non-responders to IS. Their treatment was switched to oral steroids after two
weeks (starting with oral prednisolone, 0.5 mg/kg bodyweight; at least 50 mg per day). All of these patients responded
to the prednisolone. None of non-responders presented with increased symptoms of RP and required oxygen and / or
hospitalization (RP grade III). The median follow-up after IS treatment initiation was 18 months (range: 4–66 months).
The median duration of IS treatment and prednisolone treatment was 8.2 months (range: 3.0–48.3 months) and
11.4 months (range: 5.0–44.0 months), respectively. Of the 18 IS treatment responders, 2 (11.1 %) patients with pre-
existing grade 2 COPD still required IS (400 μg twice a day) 45.0 and 48.3 months after radiotherapy, respectively. For
the remaining 16 responders (88.9 %), IS therapy was stopped after 7.7 months (range: 3.0–18.2 months). None of the
patients treated with IS developed any specific IS-related side effects such as oral candidiasis.
Conclusion: This single-centre experience shows that high-dose IS is an individual treatment option for radiation-
induced pneumonitis grade II in patients with a good performance status.
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Introduction
Lung cancer is a leading cause of cancer deaths worldwide
[21] and is frequently treated with irradiation. Radiation
pneumonitis (RP) in lung cancer patients usually occurs
within 1 to 3 months after radiotherapy [38]. The optimal
dose of radiotherapy is often limited due to normal lung
tissue constraints [22]; particularly, RP is one of the most
significant dose-limiting factors in the radiation treatment
of non-small cell lung cancer (NSCLC; [3, 23]).
The lung volume that is irradiated is of great import-
ance. When smaller lung volumes are irradiated (e.g., in
breast cancer), clinically relevant RP rates are relatively
low (<3 %), and pneumonitis is often transient and clin-
ically mild [19, 20]. The use of higher radiation doses
and the irradiation of larger lung volumes in combin-
ation with chronic lung diseases results more likely in
clinically relevant pneumonitis [11, 18]. In approximately
25–30 % of lung cancer patients, mild to severe RP can
be observed following definitive radiotherapy with 60–
70 Gray (Gy) [11, 13, 15].
The clinical symptoms of RP include dyspnea, non-
productive cough, pleuritic chest pain, fever and, rarely,
acute respiratory distress syndrome (ARDS; [5, 6, 27]).
In addition to the clinical symptoms, lung function parame-
ters such as vital capacity (VC), forced expiratory volume
(FEV1) and diffusion-capacity (DLCO) might be helpful in
quantifying the impact of RP [7].
In a prospective study on the prevention of RP in 57
lung cancer patients, the authors supported the con-
tinuous application of steroids during the course of and
following radiotherapy for preventing RP when the use
of inhalative beclomethasone was superior to oral pred-
nisolone in terms of better local efficacy and decreased
unwanted side effects [22].
The most recent S2 guideline from the German Soci-
ety for Radiation Oncology (DEGRO) recommends oral
steroids for the symptomatic therapy of clinically rele-
vant RP (DEGRO S2 guideline, Version 1.2, February
2015). Compared to inhalative steroids (IS), oral steroids
have more pronounced side effect profiles; hypergly-
caemia, weight gain, insomnia, osteoporosis, myopathy
and cognitive disorders have been associated with long-
term oral steroid treatment [4, 32].
In the presented analysis, we retrospectively assessed
the efficacy of inhalative steroids in lung cancer patients
with symptomatic RP grade II. Furthermore, as a second-
ary objective we tried to ascertain patient- and treatment-
related parameters of IS resistance and performed an
overall survival (OS) analysis.
Material and methods
Patients’ parameters
Between 05/09 and 07/10, 24 (female, n = 8; male, n =
16) patients with lung cancer were treated at a single
institution with definitive chemoradiation (CRT) to the
primary tumour site and involved hilar/mediastinal
lymph nodes and developed grade II symptomatic RP.
The presence of RP was recorded according to the Com-
mon Toxicity Criteria version 4.0 (National Cancer Insti-
tute Common Terminology Criteria for Adverse Events
[CTCAE]).
In four of the patients (16.6 %), chemotherapy was
omitted due to comorbidities, and in two of the patients
(8.3 %), sequential chemotherapy was administered.
Histologic analysis revealed NSCLC (n = 19) and SCLC
(n = 3). The cancer histology could not be determined in
2 of the patients because sampling was considered to be
too dangerous due to anticoagulation. The UICC stage
distribution was as follows: IB, one patient (4.2 %); IIB,
three patients (12.5 %); IIIA, four patients (16.7 %); IIIB,
five patients (20.1 %); IV, eight patients (33.3 %); and
limited-stage SCLC, three patients (12.6 %). The mean
patient age at the start of CRT was 66 years (range: 50–
82 years), and the mean follow-up period after CRT was
18.1 months (range: 4–65 months). The patient and
treatment characteristics are summarised in Table 1.
Radiotherapy
In all of the patients, radiotherapy was based on a plan-
ning CT scan (slice thickness 3 mm) and three-
dimensional (3D) treatment planning. The gross tumour
volume (GTV) of each tumour was identified by com-
puted tomography, PET, and bronchoscopy. Mediastinal
lymph nodes with short axis diameters ≥1.0 cm and pre-
treatment PET scans with standardised uptake values
(SUV) >3 were included. The clinical target volume
(CTV) was defined as the GTV plus a 0.5 cm margin to
account for microscopic tumour extension. For the plan-
ning target volumes (PTV), the CTVs were enlarged to
allow for organ motion and set-up variation, and they
were expanded by at least 1 cm in all directions. De-
finitive image-guided hypo-fractionated stereotactic
radiotherapy (hfSRT) was performed in three of the
patients (12.5 %). In these patients, on-board cone-
beam computed tomography was used to confirm the
correct positioning. Set-up errors were corrected be-
fore each irradiation treatment. For hfSRT, the CTV
included GTV with a safety margin of 2–3 mm, and
the PTV was defined as the CTV with a lateral safety
margin of 5 mm and a craniocaudal safety margin of
5–8 mm. One patient (4.2 %) received conventional
radiotherapy followed by sequential chemotherapy.
In general, irradiation was administered using a con-
formal multifield technique with 6- to 10-MV photons
that were delivered by a linac accelerator. Quantitative
dose-volume analysis was performed using cumulative
dose-volume histograms (DVH) to ensure that the mean
lung dose (MLD) was below 15 Gy and that the mean
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V20 and V30 were below 27 % and 20 %; the median
dose for CRT was 60.0 Gy (range: 40–70 Gy), with daily
single doses of 2.0 Gy (n = 20; 83.3 %). The single doses
for hfsRT (n = 4; 16.7 %) were 6.0 and 12.5 Gy, which
summed to the total doses of 37.5 Gy and 56 Gy,
respectively.
Diagnosis and treatment of RP
RP was diagnosed based on the typical clinical symp-
toms such as new or increased dyspnea, non-productive
cough, pleuritic chest pain and fever. In each patient, a
computed tomography (CT) scan of the chest was per-
formed within a week to radiographically verify the RP
diagnosis. A second CT scan was performed six to eight
weeks later, and after another six to eight weeks, a third
CT was performed. Thereafter, a chest and abdominal
CT was routinely performed every 3 months or in cases
of clinical signs of progressive disease. Each patient had
an oncological follow-up visit after each CT scan. All pa-
tients had RP grade II, because no patient presented
with severe symptoms requiring oxygen therapy and / or
hospitalization [28]. Patients were informed that IS ther-
apy in symptomatic RP represents an individual treat-
ment which deviates from current guidelines [33]. All
patients gave their consent.
RP treatment was initiated with the inhalative steroid
budesonide, at a dose of 800 μg twice daily (Pulmicort®
800 μg 1-0-1). One patient (4.2 %) required a non-
steroidal anti-inflammatory drug for pain relief due to
pleuritic chest pain. Upon the demands of two patients
(8.3 %), simultaneous therapy with long-lasting ß2-sym-
pathomematic salmeterol (50 μg twice daily) was initi-
ated. Within 2 weeks of IS therapy initiation, the
patients had a follow-up visit to assess treatment effi-
cacy. If a patient’s clinical symptoms were not signifi-
cantly ameliorated, the IS treatment was stopped, and
the patient was switched to oral prednisolone (0.5 mg/kg
bodyweight, with an initial dose of at least 50 mg per
day). The prednisolone dose was halved every five days
Table 1 Patients’ characteristics and statistical analysis. IS non-
responders were defined as patients with no significant








n = 6 n = 18
Median age (years) 63.3 65.2 0.680





IB 0 1 0.762
IIB 1 2 0.696
IIIA 0 4 0.304
IIIB 2 4 0.662
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Non-smoker 1 4 0.634
Former smoker 5 13 0.520
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Table 1 Patients’ characteristics and statistical analysis. IS non-
responders were defined as patients with no significant
improvement of clinical symptoms to the inhalative therapy







None 1 2 0.597
Concurrent 4 16 0.366
Sequential 1 0 0.730
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until the maintenance dose of 6 mg per day was attained;
this dose was continued for an additional 6 weeks. The pa-
tients who showed no significant improvement of clinical
symptoms within 2 weeks of IS treatment initiation were
classified as non-responders. Vice versa patients who re-
ported on mild improvement of symptoms or stable clin-
ical symptoms were also classified as non-responders.
With the support of CT, IS therapy in the responders
was tapered off. Within 6–8 weeks of the initial chest
CT that was performed to confirm the RP diagnosis, the
second chest CT was performed. If no increase but ra-
ther a consolidation of ground-glass infiltrates was
found, the budesonide dose was halved to 400 μg twice
daily (Pulmicort® 400 μg 1-0-1). If a patient showed no
clinical symptoms of RP within 6–8 weeks of switching
to this dose and another chest CT confirmed decreasing
ground-glass infiltrates, the IS therapy was stopped.
Statistical analysis
The statistical analysis was performed using a commercially
available software package (SPSS V.22.0 for Windows). The
patients were dichotomised into IS responders and IS non-
responders, and they were compared according to gender,
age, histology, various lung function parameters and lung
doses Chi-square tests were carried out to assess the vari-
ous patient- and treatment-related parameters and patient
response to inhalative steroids, and a OS analysis using
Kaplan-Meier curves and log-rank test was performed.
Results
Symptomatic RP manifested a median of 2.8 months
after radiotherapy (range: 1–5 months). No oxygen re-
quiring (grade III), life-threatening (grade IV) or lethal
(grade V) pneumonitis cases were observed.
In each patient, a chest CT confirmed the clinical diag-
nosis by showing blurred interstitial markings with spotty
and partially confluent infiltrates, which are typical radio-
graphic signs of pneumonitis.
According to the severity of the patients’ clinical symp-
toms, all 24 patients had RP grade II, because no patient
required oxygen, which is the defining criterion for RP
grade III.
Eighteen patients (75.0 %) were classified as responders
to IS treatment; they presented with significantly de-
creased clinical symptoms within two weeks of IS treat-
ment initiation. In all of these patients (18/18), the second
CT, which was performed 6–8 weeks after the clinical and
radiographic diagnosis of RP, showed decreased ground-
glass opacities. This was confirmed in the subsequent CT,
performed 6–8 weeks after. IS was taken for a median of
8.2 months (range: 3.0 – 48.3 months). Of the IS treat-
ment responders, 2 (11.1 %) patients with pre-existing
COPD grade II still required IS treatment (400 μg twice
daily) at 45.0 and 48.3 months after radiotherapy,
respectively. For the remaining 16 responders (88.9 %), IS
therapy was stopped after 7.7 months (range: 3.0–
18.2 months).
Of the 24 patients, 6 (25 %) showed no significant im-
provements in clinical symptoms two weeks after IS
therapy initiation; in these cases, treatment was switched
to oral prednisolone. In the 2-week interval after initi-
ation of IS therapy until response assessment, in no pa-
tient neither an aggravation of clinical symptoms nor
oxygen requiring dyspnea (RP grade III) was observed.
Prednisolone was taken for a median of 11.4 months
(range: 5.0–44.0 months). Two patients required oral
steroids until their death 16 and 44 months after radio-
therapy due to brain metastases and drug-induced toxic
diffuse alveolitis by amiodarone, respectively.
None of the patients who were treated with IS devel-
oped any specific IS-related side effects such as oral can-
didiasis. In contrast, every patient who was treated with
oral steroids experienced at least one of the following
side effects: appetite increase with weight gain, sleep
disturbances, mood changes, and lower leg oedema. A
patient with known diabetes experienced increased
blood sugar values during treatment with oral steroids
and required a new diabetes treatment.
At time of analysis, seven patients (29.2 %) were alive
and free of disease, and seventeen (70.8 %) were
deceased. None of the patients had died from fatal pneu-
monitis. One of the patients (4.2 %) who did not re-
spond to IS died from congestive heart failure
20 months after radiotherapy. Sixteen (66.7 %) patients
died from cancer-related conditions.
The patient and treatment parameters are summarised
in Table 1. No statistically significant associations were
found between the various patient- and treatment-related
parameters and patient response to inhalative steroids.
We observed a trend towards statistical significance (p =
0.077) with respect to HbCO level (0.3 % vs. 2.2 %). The
median OS of the responders was 27.5 months compared
with 11.9 months of the non-responders (p = 0.073; log-
rank test). The Kaplan Meier curves and the survival chart
are presented in Fig. 1 and Table 2, respectively.
Discussion
RP is a fairly common subacute side effect of radiother-
apy in lung cancer patients; it has a reported incidence
of 10–30 %. This incidence range likely arises from dif-
ferent patient populations, the subjective scoring of RP
and treatment-related factors [25].
The application of oral steroids is recommended for
the treatment of symptomatic RP. However, the therapy
is not causally but merely symptomatic; the progression
of RF is unlikely to be influenced [9, 12, 31]. Several
agents, such as TNF-alpha and TGF-beta inhibitors,
have been tested as causal treatments for RP to interrupt
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the development of fibrosis; however, none of them have
been been established in clinical practice [34].
Oral steroids suppress the symptoms of pneumonitis.
In contrast to the oral application of steroids, the inhala-
tive application of steroids has a lower risk of systemic
side effects, such as weight gain, hyperglycaemia, sleep
disturbances, mood changes and oedemas [4, 32]. In our
study, at least one of these side effects was observed in
each of the seven patients who did not respond to IS
and required oral prednisolone. This is important be-
cause oral steroids must be taken for approximately two
months to prevent the exacerbation of symptoms [24].
Pagel et al. [22] tried to reduce the incidence of RP
with the prophylactic application of either oral or inhala-
tive steroids; the authors compared the application of
the systemic and inhalative approaches. Inhalative beclo-
methasone was found to be superior to oral prednisol-
one in terms of better local efficacy and decreased
unwanted side effects. In line with these results, the ap-
plication of inhalative steroids in the therapeutic setting
seems to be consistent.
In the present study, IS were taken for a median of
8.2 months. Although this may appear to be a long time,
the recommendation for taking oral steroids is at least
two months to avoid symptom exacerbation ([24],
DEGRO S2 guideline, Version 1.2, February 2015). We
decided to slowly taper off IS treatment; the IS dose was
reduced only when a chest CT scan 6–8 weeks after initi-
ation of IS therapy confirmed the regression of the typical
radiographic signs of RP. The efficacy of this strategy was
confirmed by the fact that none of the responders experi-
enced symptom exacerbation during the stepwise reduc-
tion of IS treatment.
Six patients (25 %) did not report on a significant
improvement of clinical symptoms after two weeks of IS
and were classified a non-responders. Their therapy was
switched to oral prednisolone. No statistically significant
differences were found in the various patient- and
treatment-related parameters, including spirometric mea-
sures, before radiotherapy between the responders and
non-responders. Several of the patient- and treatment-
related parameters may have influenced the patient re-
sponse to IS.
Important treatment-related parameters include the
dose-volume parameters of radiotherapy [29] and appli-
cation of chemotherapy [16]. To prevent the occurrence
of RP, the irradiated volume should be as low as possible.
There is considerable evidence that the risk of late lung
toxicity is a function of dose-volume parameters includ-
ing the mean lung dose (MLD) and certain volumes of
the lung that receive different cumulative doses. As a
general rule, the risk for symptomatic RP sharply in-
creases with a MLD >20 Gy, V20 > 30 % and V30 > 20 %,
respectively [29, 35, 37]. For our patients, the MLD was
kept below 15 Gy, and the mean V20 and V30 were kept
below 27 % and 20 %, respectively. Nevertheless, there is
no general threshold dose for developing symptomatic
RP [1].
In some studies, chronic obstructive pulmonary dis-
ease (COPD) was associated with radiation-induced lung
toxicity [30], whereas other studies reported no statisti-
cally significant relationship [8, 36]. However, pre-
existing COPD may have contributed to patient non-
response to IS because clinical symptoms, including dys-
pnea, are also typical of COPD exacerbation; thus, an
overlap between COPD and RP may have contributed to
patient non-response to IS.
Older age and the application of concurrent chemo-
therapy seem to be risk factors for more severe RP after
radiation [12, 16], while active smoking seems to have a
protective effect [10, 26]. However, opinions vary regard-
ing the effects of smoking on RP, and some studies have
identified smoking as a risk factor for pneumonitis [26].
We found a trend towards lower HbCO levels in non-
Fig. 1 Overall survival of all patients (left), and differences (right) between responders (blue curve) and non-responders (green curve)
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responders (0.3 % vs. 2.2 %), which potentially reflects
patient smoking habits, although only 1 of the patients
who responded well to the IS therapy was an active
smoker. There might be a bias between the responder
and non-responder groups because we only collected
information on smoking status at the time of diagnosis.
We did not know whether any of the patients started
smoking after their diagnosis again or made false
statements.
While smoking may be a protective factor against de-
veloping RP [9], smoking could also be a factor for bet-
ter inhalative IS treatment response compared to
quitting smoking or never smoking at all. This might be
due to changes in the immune response of smokers
compared to non-smokers [14].
None of the non-responders were alive at time of ana-
lysis. We are convinced that there was no relationship
between non-response and poor survival because all of
the patients showed good symptom relief after initiating
oral corticosteroid therapy. Rather, 3/6 (50.0 %) patients
initially presented with UICC stage IV lung cancer, and
two (33.3 %) of the patients had UICC stage IIIB lung
cancer, which are generally associated with very poor
prognoses [2]. Furthermore, Inoue et al. [16] showed in
a series of 256 lung cancer patients that mild RP had in
contrast to severe RP no impact on the overall survival.
This suggests that steroids act only as symptomatic ther-
apy but do not prevent lung tissue damage.
The limitations of our study include its retrospective
design and the relatively small sample size. The small
sample size likely influenced the statistical analysis
because we were unable to show significant differences
between the IS treatment responders and non-
responders. Therefore, it was not possible to identify
treatment- and patient-related parameters associated
with patient response or non-response to inhalative
budesonide. Furthermore, therapy was controlled on the
basis of the severity of clinical symptoms and regression
of radiographic signs of RP on the CT scans. We do not
know whether the introduction of regularly measured
Table 2 Results of the long-rank test showing in detail the cumulative proportion of survivors, number of deaths and patients at risk
in each group at the different follow-up time points








1 4 0.94 1 17
2 5 0.89 2 16
3 6 0.83 3 15
4 7.7 0.78 5 14
5 9.1 0.72 6 13
6 10.0 0.67 7 12
7 13.0 0.61 8 11
8 20.2 0.56 9 10
9 27.4 0.5 9 9
10 27.7 - 9 8
11 45.0 - 9 7
12 48.3 - 9 6
13 48.9 0.42 10 5
14 49.6 0.33 11 4
15 51.7 - 11 3
16 52.6 – 11 2
17 65.6 - 11 1
18 67.4 - 11 0
Non-Responder to IS
1 7.0 0.83 1 5
2 11.0 0.67 2 4
3 11.9 0.5 3 3
4 12.9 0.33 4 2
5 16.0 0.17 5 1
6 47.0 0 6 0
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lung function parameters and blood gas analysis would
have improved patient selection for IS therapy and the
response rate to IS therapy, although blood gas analysis
failed to show utility for diagnosis and treatment of RP
in the largest published series with 385 patients by
Sekine et al. [31]. The treatment of RP still depends on
the experience of the clinician [16, 31]. Additionally,
there are no data about the time interval, in which a re-
sponse to IS can be expected. Therefore, we do not
know if the interval from initiation of IS therapy until
clinical response assessment was too long, although RP
is known to responds better to steroids than drug-
induced interstitial lung disease [17].
As even no aggravation of clinical symptoms in the
group of non-responders to IS therapy was observed, and
only the lack of significant improvement of the clinical
symptoms led to the decision to switch inhalative budeso-
nide to oral prednisolone, we believe that our approach in
this selected cohort of patients was safe. Additionally, it is
important to emphasize that no patient with an ECOG
Score ≥2 was selected for IS therapy. Therefore, no gen-
eral statements can be made about patients with poor per-
formance status.
However, despite these limitations, we are convinced
that our report makes useful contributions to the discus-
sion on the individualised treatment of symptomatic RP
grade II in lung cancer patients after radiotherapy.
Conclusion
As an individual treatment in patients with a good per-
formance status, symptomatic RP grade II in lung cancer
patients after radiotherapy can be initially treated with
inhalative steroids, leaving the application of oral ste-
roids for non-responders. Requirements are close obser-
vation of the patient and considerable experience with
RP of the clinician.
Competing interest
The authors declare that they have no competing interests
Author’s contributions
HC and JS are equally contributing authors and were responsible for
conception, analysis, interpretation of data and wrote the manuscript. LK and
LMM made substantial contribution to acquisition of data and writing the
manuscript. MA did the statistical tests. BM and DN were revising the
manuscript critically for important intellectual content. All authors reviewed
and approved the final manuscript.
Acknowledgment
We thank Bernhard Vaske from the Institute of Medical Biometry and
Informatics, Hannover Medical School, for his statistical support.
Author details
1Department of Radiation Oncology, Hannover Medical School,
Carl-Neuberg-Str. 1, 30625 Hannover, Germany. 2Hannover Joint Practice in
Radiooncology, Rundestr. 10, 30161 Hannover, Germany. 3Ibbenbüren
Hospital Thoracic and Lung Center, Große Str. 41, 49477 Ibbenbüren,
Germany. 4Hildesheim Goslar Joint Practice in Radiooncology,
Senator-Braun-Allee, 31135 Hildesheim, Germany. 5Department of
Pneumology, Thoracic Oncology and Respiratory Medicine, Frankenburgstr,
31, 48431 Rheine, Germany. 6Department of Radiation Oncology, University
of Lübeck, Lübeck, Germany. 7Department of Radiotherapy and Special
Oncology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover,
Germany.
Received: 14 September 2015 Accepted: 16 December 2015
References
1. Claude L, Perol D, Ginestet C. A prospective study on radiation pneumonitis
following conformal radiation therapy in non-small-cell lung cancer: clinical
and dosimetric factors analysis. Radiother Oncol. 2004;71(2):175–81.
2. Christodoulou M, Bayman N, McCloskey P,Rowbottom C, Faivre-Finn C. New
radiotherapy approaches in locally advanced non-small cell lung cancer. Eur
J Cancer. 2014;50(3):525–34.
3. Dang J, Li G, Lu X, Yao L, Zhang S, Yu Z. Analysis of related factors
associated with radiation pneumonitis in patients with locally advanced
non-small-cell lung cancer treated with three-dimensional conformal
radiotherapy. J Cancer Res Clin Oncol. 2010;136(8):1169–78.
4. De Vries M, Berendsen AJ, Bosveld HE ,Kerstjens HA, van der Molen T. COPD
exacerbations in general practice: variability in oral prednisolone courses.
BMC Fam Pract; 2012. doi:10.1186/1471-2296-13-3.
5. Dörr W, Bertmann S, Herrmann T. Radiation induced lung reactions in
breast cancer therapy. Modulating factors and consequential effects.
Strahlenther Onkol. 2005;181(9):567–73.
6. Dörr W, Baumann M, Herrmann T. Radiation-induced lung damage: a
challenge for radiation biology, experimental and clinical radiotherapy. Int J
Radiat Biol. 2000;76(4):443–6.
7. Enache I, Noel G, Jeung MY, Meyer N, Oswald-Mammosser M, Pistea C, et al.
Impact of 3D conformal radiotherapy on lung function of patients with
lung cancer: a prospective study. Respiration. 2013;86(2):100–08.
8. Fay M, Tan A, Fisher R, Mac Manus M, Wirth A, Ball D. Dose-volume
histogram analysis as predictor of radiation pneumonitis in primary lung
cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2005;
61(5):1355–63.
9. Fu XL, Huang H, Bentgel G, Clough R, Jirtle RL, Kong FM, et al. Predicting
the risk of symptomatic radiation-induced lung injury using both the
physical and biologic parameters V and transforming growth factor ß. Int J
Radiat Oncol Biol Phys. 2001;50(4):899–908.
10. Franzen L, Bjermer L, Hendriksson R, Littbrand B, Nilsson K. Does smoking
protect against radiation-induced pneumonitis? Int J Radiat Oncol Biol Phys.
1989;56(5):721–4.
11. Graham MW, Purdy JA, Emami B, Harms W, Bosch W, Lockett MA et al. Clinical
dose-volume histogram analysis for pneumonitis after 3D treatment for non-
small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999;45(2):323–9.
12. Hernando ML, Marks LB, Bentel GC, Zhou SM, Hollis D, Das SK, et al.
Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in
201 patients with lung cancer. Int J Radiat Oncol Biol Phys. 2001;51(3):650–9.
13. Hernberg M, Virkkunen P, Maasilta P, Keyriläinen J, Blomqvist C, Bergh J et
al. Pulmonary toxicity after radiotherapy in primary breast cancer patients:
results from a randomized chemotherapy study. Int J Radiat Oncol Biol Phy.
2002;52(1):128–36.
14. Höller U, Feyer P. Management und Prophylaxe von organbezogenen
Toxizitäten – Pneumotoxizität unter Strahlentherapie. Im Focus Onkologie.
2007;9:61–7.
15. Hurkmans CW, Borger JH, Bos LJ, van der Horst A, Pieters BR, Lebesque JV et al.
Cardiac and lung complication probabilities after breast cancer irradiation.
Radiother Oncol. 2000;55(2):145–51.
16. Inoue A, Kunitoh H, Sekine I, Sumi M, Tokuuye K, Saijo N. Radiation
pneumonitis in lung cancer patients: a retrospective study of risk factors
and long-term prognosis. Int J Radiat Oncol Biol Phys. 2001;49(3):649–55.
17. Kim S, Park SY, Song JH, Song JH, Seon HJ, Kim YH et al. Corticosteroid
therapy against treatment-related pulmonary toxicities in patients with lung
cancer. J Thorac Dis. 2014;6(9):1209–17.
18. Kwa SL, Lebesque JV, Theuws JC, Marks LB, Munley MT, Bentel G et al.
Radiation pneumonitis as a function of mean lung dose: an anlysis of
pooled data of 540 patients. Int J Radiat Oncol Biol Phy. 1998;42(1):1–9.
19. Lind P, Marks LB, Hardenberg PH, Clough R, Fan M, Hollis D et al. Technical
factors associated with radiation pneumonitis after local +/− regional
radiation therapy for breast cancer. Int J Radiat Oncol Biol Phys. 2002;52(1):
137–43.
Henkenberens et al. Radiation Oncology  (2016) 11:12 Page 7 of 8
20. Lingos TI, Recht A, Vicini F, Abner A, Silver B, Harris JR. Radiation
pneumonitis in breast cancer patients treated with conservative surgery and
radiation therapy. Int J Radiat Oncol Biol Phys. 1991;21(2):355–60.
21. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer
J Clin. 2005;55(2):74–108.
22. Pagel J, Mohorn M, Kloetzer KH, Fleck M, Wendt TG . Inhalative versus
systemische Pneumonitisprophylaxe bei Thoraxbestrahlungen. Strahlenther
Onkol. 1998;174(1):25–9.
23. Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A et al.
Use of normal tissue complication probability models in the clinic. Int J
Radiat Oncol Biol Phys. 2010;76(3):10–9.
24. McCarty MJ, Lilis P, Vukelja SJ. Azathioprine as a steroid-sparing agent in
radiation pneumonitis. Chest. 1996;109(5):1397–400.
25. Mao J, Kocak Z, Zhou S, Garst J, Evans ES, Zhang J et al. The impact of
induction chemotherapy and the associated tumor response and
subsequent radiation-related changes in lung function and tumor response.
J Radiat Oncol Biol Phys. 2007;27(5):1360–69.
26. Monson JM, Stark P, Reilly JJ, Sugarbaker DJ, Strauss GM, Swanson SJ et al.
Clinical radiation pneumonitis and radiographic changes after thoracic
radiation therapy for lung carcinoma. Cancer. 1998;82(5):842–50.
27. Müller G, Kiricuta IC, Stieß J, Bohndorf, W. Strahlenpneumonitis und
Lungenfibrose nach CT-geplanter Radiotherapie des Bronchialkarzinoms.
Strahlenther Onkol. 1994;170(7):400–7.
28. National Cancer Institute: Common Terminology Criteria for Adverse Events
(CTCAE) v.4.0. http://ctep.cancer.gov/protocolDevelopment/electronic_
applications/ctc.htm. Accessed 22/06/2015
29. Seppenwoolde Y, Lebesque JV, de Jaeger K, Belderbos JS, Boersma LJ,
Schilstra C et al. Comparing different NTCP models that predict the
incidence of radiation pneumonitis. Normal tissue complication probability.
Int J Radiat Oncol Biol Phys. 2003;55(3):724–35.
30. Robnett TJ, Machtay M, Vines EF, McKenna MG, Algazy KM, McKenna WG.
Factors predicting severe radiation pneumonitis in patients receiving
definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys. 2000;
48(1):89–94.
31. Sekine I, Sumi M, Ito Y, Nokihara H, Yamamoto N, Kunitoh H et al.
Retrospective analysis of steroid therapy for radiation-induced lung injury in
lung cancer patients. Radiother Oncol. 2006;80(1):93–7.
32. Steen NE, Methlie P, Lorentzen S, Hope S, Barrett EA, Larsson S et al.
Increased systemic cortisol metabolism in patients with schizophrenia
and bipolar disorder: a mechanism for increased stree vulnerability. J
Clin Psychiatry. 2011;72(11):1515–21.
33. S2 guideline “supportive care in radiation oncology” by the DEGRO, Version
1.2, February 2015. http://degro.org/dav/html/leitlinien/LLSupportivtherapie.
pdf. Accessed 22 June 2015
34. Tsoutsou PG. The interplay between radiation and the immune system in
the field of post-radical pneumonitis and fibrosis and why it is important to
understand it. Expert Opin Pharmacother. 2014;15(13):1781–83.
35. Tsujino K, Hirota S, Endo M, Obayashi K, Kotani Y, Satouchi M et al.
Predictive value of dose-volume histogram parameters for predicting
radiation pneumonitis after concurrent chemoradiation for lung cancer. Int
J Radiat Oncol Biol Phys. 2003;55(1):110–5.
36. Wang S, Liao Z, Wei X, Liu HH, Tucker SL, Hu CS et al. Analysis of clinical
and dosimetric factors associated with treatment-related pneumonitis (TRP)
in patients with non-small-cell lung cancer (NSCLC) treated with concurrent
chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int
J Radiat Oncol Biol Phys. 2006;66(5):1399–407.
37. Yorke ED, Jackson A, Rosenzweig KE, Braban L, Leibel SA, Ling CC.
Correlation of dosimetric factors and radiation pneumonitis for non-small-
cell lung cancer patients in a recently completed dose escalation study. Int
J Radiat Oncol Biol Phys 2005. 2005;63(3):672–82.
38. Zhang XJ, Sun JG, Sun J, Ming H, Wang XX, Wu L, et al. Prediction of
radiation pneumonitis in lung cancer patients: a systematic review. J Cancer
Res Clin Oncol. 2012;138(12):2010–16.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Henkenberens et al. Radiation Oncology  (2016) 11:12 Page 8 of 8
